Cullinan Therapeutics (CGEM) Cash from Operations: 2020-2023
Historic Cash from Operations for Cullinan Therapeutics (CGEM) over the last 4 years, with Dec 2023 value amounting to -$18.1 million.
- Cullinan Therapeutics' Cash from Operations rose 27.43% to -$18.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$134.3 million, marking a year-over-year decrease of 6.01%. This contributed to the annual value of -$145.3 million for FY2024, which is 8.21% down from last year.
- Per Cullinan Therapeutics' latest filing, its Cash from Operations stood at -$18.1 million for Q4 2023, which was up 46.89% from -$34.1 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Cash from Operations ranged from a high of -$1.5 million in Q1 2021 and a low of -$54.4 million during Q3 2022.
- For the 3-year period, Cullinan Therapeutics' Cash from Operations averaged around -$25.4 million, with its median value being -$23.4 million (2022).
- Its Cash from Operations has fluctuated over the past 5 years, first spiked by 69.79% in 2021, then tumbled by 1,346.07% in 2022.
- Quarterly analysis of 4 years shows Cullinan Therapeutics' Cash from Operations stood at -$9.4 million in 2020, then slumped by 60.78% to -$15.2 million in 2021, then plummeted by 64.68% to -$25.0 million in 2022, then climbed by 27.43% to -$18.1 million in 2023.
- Its last three reported values are -$18.1 million in Q4 2023, -$34.1 million for Q3 2023, and -$31.0 million during Q2 2023.